UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

The Lancet (British edition), 2010-07, Vol.376 (9737), p.235-244

2010

Volltextzugriff (PDF)

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

The Lancet (British edition), 2010-07, Vol.376 (9737), p.245-251

2010

Volltextzugriff (PDF)

MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients

Genes chromosomes & cancer, 2022-03, Vol.61 (3), p.148-160

2022

Volltextzugriff (PDF)

MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial

BMC cancer, 2020-01, Vol.20 (1), p.81-81, Article 81

2020

Volltextzugriff (PDF)

BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance

Breast cancer research and treatment, 2022-10, Vol.195 (3), p.263-274

2022

Volltextzugriff (PDF)

Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition

Pharmacogenomics and personalized medicine, 2014-01, Vol.7 (default), p.307-316

Audeh, M William

2014

Volltextzugriff (PDF)

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

Journal of clinical oncology, 2015-01, Vol.33 (3), p.244-250

2015

Volltextzugriff (PDF)

Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging

Breast cancer research and treatment, 2015-10, Vol.153 (3), p.607-616

2015

Volltextzugriff (PDF)

Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study

Investigational new drugs, 2013-10, Vol.31 (5), p.1345-1354

2013

Volltextzugriff (PDF)

Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

Gynecologic oncology, 2016-02, Vol.140 (2), p.199-203

2016

Volltextzugriff (PDF)

Reply to W. Altundag

JCO precision oncology, 2022-08 (6)

Audeh, William

2022

Volltextzugriff (PDF)

HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles

Modern pathology, 2022-08, Vol.35 (8), p.1075-1082

2022

Volltextzugriff (PDF)

Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial

Journal of clinical oncology, 2024-10, Vol.42 (30), p.3561-3569

2024

Volltextzugriff (PDF)

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

The lancet oncology, 2020-04, Vol.21 (4), p.519-530

2020

Volltextzugriff (PDF)

A breast cancer gene signature for indolent disease

Breast cancer research and treatment, 2017-07, Vol.164 (2), p.461-466

2017

Volltextzugriff (PDF)

Gene expression associated with lymphovascular invasion and genomic risk in early-stage breast cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.559-559

2021

Volltextzugriff (PDF)

Current Status of Anti–Human Epidermal Growth Factor Receptor 2 Therapies: Predicting and Overcoming Herceptin Resistance

Clinical breast cancer, 2013-08, Vol.13 (4), p.223-232

2013

Volltextzugriff (PDF)

Abstract PS6-19: Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS6-19-PS6-19

2021

Volltextzugriff (PDF)

Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer

Breast cancer research and treatment, 2018-04, Vol.168 (3), p.625-630

2018

Volltextzugriff (PDF)

Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype

Modern pathology, 2024-08, Vol.37 (8), p.100530, Article 100530

2024

Volltextzugriff (PDF)

The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy

Annals of surgical oncology, 2023-12, Vol.30 (13), p.8353-8361

2023

Volltextzugriff (PDF)

Abstract P2-08-06: Defining transcriptomic profiles of breast cancer with early lymph node metastases: A FLEX database sub-study

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P2-P2-08-06

2022

Volltextzugriff (PDF)

Abstract P4-07-32: Mammaprint and Blueprint are prognostic of outcome following neoadjuvant chemotherapy

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P4-P4-07-32

2022

Volltextzugriff (PDF)

ASO Visual Abstract: The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy

Annals of surgical oncology, 2024, Vol.31 (1), p.393-394

2024

Volltextzugriff (PDF)

Impact of race on BluePrint genomic subtyping in HER2+ breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.564-564

2023

Volltextzugriff (PDF)

1 – 25 von 128

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(124)
Mit Volltextzugriff
(108)

Publikationsform

Artikel
(128)

Sprache

Englisch
(128)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(35)
Science & Technology
(35)
Humans
(30)
Oncology
(28)
Breast Cancer
(24)
Female
(22)
Chemotherapy
(15)
Aged
(14)
Middle Aged
(13)
Adult
(12)
Tumors
(12)
Breast Neoplasms - Drug Therapy
(11)
Medicine
(11)
Medicine & Public Health
(11)
Breast Neoplasms - Genetics
(10)
Cancer Therapies
(10)
Antineoplastic Agents - Therapeutic Use
(9)
Breast Neoplasms - Pathology
(9)
Erbb-2 Protein
(9)
Genomics
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients

MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial

BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance

Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging

Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study

Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

Reply to W. Altundag

HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles

Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

A breast cancer gene signature for indolent disease

Gene expression associated with lymphovascular invasion and genomic risk in early-stage breast cancer

Current Status of Anti–Human Epidermal Growth Factor Receptor 2 Therapies: Predicting and Overcoming Herceptin Resistance

Abstract PS6-19: Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens

Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer

Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype

The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy

Abstract P2-08-06: Defining transcriptomic profiles of breast cancer with early lymph node metastases: A FLEX database sub-study

Abstract P4-07-32: Mammaprint and Blueprint are prognostic of outcome following neoadjuvant chemotherapy

ASO Visual Abstract: The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy

Impact of race on BluePrint genomic subtyping in HER2+ breast cancer

Suchergebnisse filtern